Journal
British Journal of Haematology, 2020
Authors
Lourdes Calvente, Rosemarie Tremblay-LeMay, Wei Xu, Fong Chun Chan, Michael Hong, Tong Zhang, Ho-Young Yhim, John Kuruvilla, Michael Crump, Vishal Kukreti, Anca Prica, Dean Regier, Marco A Marra, Aly Karsan, Christian Steidl, David W Scott, Peter Sabatini, Robert Kridel.

Despite continuing improvements in the management of classical Hodgkin lymphoma (cHL), relapse remains associated with a risk of lymphoma-related mortality. The biological composition of relapse tumour biopsies shows interpatient variability, which can be leveraged to design prognostic biomarkers. Here, we validated the RHL30 assay, a previously reported gene expression model in an independent cohort of 41 patients with relapsed cHL. Patients classified as high-risk by the RHL30 assay had inferior failure-free survival (FFS) after autologous stem cell transplantation (2-year FFS 41% vs. 92%, P = 0ยท035). The RHL30 model is a robust biomarker that risk-stratifies patients considered for autologous stem cell transplantation.

Learn More
Back to top